Search the Newsreel

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

RedHill Biopharma Ltd. provided an update on the development of opaganib for Ebola virus disease (EVD) as confirmed Bundibugyo ebolavirus cases and deaths have substantially increased. The company is in discussions with African health authorities and research institutions regarding the potential use of opaganib, …

Redhill Biopharma Ltd (RDHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Redhill Biopharma Ltd (RDHL), focusing on its stock price momentum, support and resistance levels, and various technical indicators. The current price momentum score is 4.70, ranking 44th in the Pharmaceuticals industry, with the stock trading between a …

RedHill Biopharma (Nasdaq: RDHL) details opaganib plans amid Ebola surge

RedHill Biopharma has provided an update on its investigational antiviral opaganib for Ebola virus disease, amidst a growing outbreak of Bundibugyo ebolavirus with over 3,200 cases and 1,400 deaths by July 28, 2026. The company is actively discussing next-step planning and potential partnerships with …

Redhill Biopharma Ltd (RDHL) Institutional Confidence

This article from TradingKey provides an overview of Redhill Biopharma Ltd's (RDHL) institutional confidence, a component of its overall stock score. It lists institutional holdings and changes, showing that while some firms like Yorkville Advisors Global hold significant shares without recent changes, others like …

Redhill Biopharma Ltd (RDHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses Redhill Biopharma Ltd (RDHL) revenue breakdown but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It provides current stock information, including the price, market cap, and P/E TTM. The …

Redhill Biopharma Ltd (RDHL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Redhill Biopharma Ltd (RDHL), stating that its current valuation score is 9.96, ranking 1st in the Pharmaceuticals industry. It highlights the company's P/E ratio of -7.00, which is significantly below its recent high. However, other key financial …

Redhill Biopharma Ltd (RDHL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Redhill Biopharma Ltd (RDHL) shareholder structure, listing major shareholders and their proportional holdings, as well as institutional shareholding activities over several quarters. Key shareholders include Yorkville Advisors Global, LP., Gagnon Securities LLC, and Citadel Advisors LLC. The …

Redhill Biopharma Ltd (RDHL) Cash Flow

This article provides a comprehensive overview of Redhill Biopharma Ltd's (RDHL) cash flow statements, including operating, investing, and financing activities, spanning numerous quarters. It details quarterly financial figures and year-over-year changes for various cash flow components. The piece also includes an FAQ section explaining …

Redhill Biopharma Ltd (RDHL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Redhill Biopharma Ltd (RDHL), evaluating its volatility, financial, and investment risks. With a risk assessment score of 1.60, RDHL ranks 144 out of 155 in the Pharmaceuticals industry and exhibits a high beta of 4.99, indicating significant …

Redhill Biopharma Ltd (RDHL) Financial Health: Profitability & Balance Sheet Analysis

Redhill Biopharma Ltd (RDHL) has a financial score of 4.38, ranking 155 out of 155 in the Pharmaceuticals industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue was $1.80M, a 90.21% year-over-year decrease, with net profit falling by 106.50%. …

RDHL|Redhill Biopharma Ltd|Price:0.633|Chg%:-0.028

Redhill Biopharma Ltd (RDHL) shows relatively healthy fundamentals and high growth potential, though its valuation is considered fairly valued within the Pharmaceuticals industry. The stock has exhibited weak market performance recently and is expected to trend downwards in the medium term, trading sideways between …

Redhill Biopharma (RDHL) Q2 2022 Earnings: Massive EPS Miss as Company Reports No Revenue - Analyst Earnings Estimate

RDHL Q2 2022 Earnings: Staggering EPS Miss as Company Faces Operational Headwinds - ROA Comparison

RedHill Biopharma (RDHL) Edges Higher: Stock Tests Support at $0.70 - Weekly Profile

RedHill Biopharma Ltd. SEC Filing (Jul 14, 2026)

This article reports on RedHill Biopharma Ltd.'s SEC filing, specifically a Notice of Effectiveness for an F-3 form dated July 13, 2026. The filing indicates the effectiveness of their previously submitted shelf registration. The article also provides recent news and other SEC filings related …